KRAS and lung carcinoma: Notably, three different pharmacological PP2A-reactivating compounds resulted in similar effects on HDAC chromatin recruitment (Fig 4A–D), and DBK1154 synergized with HDACi in killing KRAS-mutant lung cancer cells (Fig S5B and C).